Acambis retained at neutral by Merrill

Merrill Lynch analyst Peter Welford retained Acambis at a neutral rating. Acambis has begun submissions to the Food and Drug Administration for approval of its smallpox vaccine, ACAM2000. Final approval could be completed by April. The market potential for a number of the company's other vaccines is uncertain. Shares of the Cambridge, England, biotechnology company were down 1 cent, or 0.14%, at $6.89 on volume of 12,650 shares versus the three-month running average of 26,581 shares. (Nasdaq: ACAM).

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.